Truscreen Group Limited (ASX:TRU)
TruScreen Group Limited (ASX:TRU) manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and Artificial Intelligence- supported (AI) process designed to detect the presence in real time of pre-cancerous and cancerous tissue on the cervix. TruScreen is a patented cervical cancer detection system with distribution agreements in more than 20 countries. The Company’s current key focus is China which accounts for over 50% of sales. Its products have been sold to Vietnam, Russia, Zimbabwe, Mexico, India, Zimbabwe and Saudi Arabia.
TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world.